Last reviewed · How we verify
Human ADME
At a glance
| Generic name | Human ADME |
|---|---|
| Sponsor | Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Tuvusertib (M1774) Human Mass Balance and Absolute Bioavailability Study (DDRIVER Solid Tumors 303) (PHASE1)
- A Study of Absorption-Distribution-Metabolism-Excretion (ADME) of [14C]IMP4297 to China Healthy Male Subjects (PHASE1)
- A Study in People With Advanced Cancer to Test How BI 907828 is Processed in the Body (PHASE1)
- Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib (PHASE1)
- Dose Response Study of Transdermal Human Insulin in Patients (PHASE2, PHASE3)
- BTZ-043 Dose Evaluation in Combination and Selection (PHASE2)
- Human Mass Balance Study of Pyronaridine (PHASE1)
- Human Absorption, Distribution, Metabolism and Excretion (ADME) of [14C]-Evobrutinib (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: